sistent pulmonary hypertension of the newborn. 5 In many patients with acute respiratory Background -Inhaled nitric oxide (NO) is a selective pulmonary vasodilator which distress syndrome (ARDS) inhaled NO reduces the pulmonary artery pressure and increases can improve gas exchange in acute lung injury. However, it is uncertain that this arterial oxygenation by lessening intrapulmonary shunt. 6 Experimentally, inhaled NO effect on arterial oxygenation can be generalised to all lung diseases.
sachusetts, USA). Total lung capacity (TLC) was measured by whole body plethysmography, and dynamic lung volumes (forced expiratory volume in one second (FEV 1 ) and forced vital capacity (FVC)) were measured with a dry wedge spirometer. Transcutaneous arterial oxygen and carbon dioxide tensions (TcP 2 , TcP 2 ) were measured, respectively, by Servomed Oxymonitor and Servomed Kapnomonitor (Hellige GmbH, Freiburg im Breisgau, Germany). Arterial oxygen saturation (Sa 2 ) was measured by pulse oximeter (Pulsox-DP7, Minolta, Tokyo, Japan) and cardiac output by the transthoracic impedance method (NCCOM 3 cardiovascular monitor, BioMed Medica Manufacturing Inc, Irvine, California, USA).
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Gas cylinders
Two way analysis of variance was used together with a paired Student's t test to assess differences between treatments. p values of less than 0.05 were considered significant. The results Bedfont Scientific Ltd, Kent, UK). Each anaare expressed as mean and standard error. lyser was calibrated with a standard gas of 80 (1) ppm NO in nitrogen and 10 ppm NO 2 (British Oxygen Company Ltd, London, UK).
The fractional inspired oxygen concentration Results
The FEV 1 was 26 (9)% predicted and the (Fi 2 ) of the inhaled gas was monitored continuously using a portable oxygen monitor FEV 1 /FVC ratio was 38 (7)% in patients with COPD (table 1) . Most patients with severe (TED 200-T, Teledyne Electronic Devices, City of Industry, California, USA). Air was pulmonary hypertension took calcium antagonists or angiotensin converting enzyme insupplied to the nasal mask by the same delivery system.
hibitors. No patient was receiving treatment with continuous intravenous infusion of proThe venous blood methaemoglobin (MetHb%) formed from inhaled NO was measured stacyclin (table 2) . The patients with severe pulmonary hypertension had high values of from samples collected from an antecubital vein before and after each inhalation period pulmonary vascular resistance (PVR). Inhaled NO reduced mean TcP 2 from 9.6 (0.3) kPa using a multiple wavelength spectrophotometric CO oximeter (IL282 CO-Oximeter, In-to 8.9 (0.4) kPa (p <0.05) in healthy volunteers and from 7.4 (0.6) kPa to 7.0 (0.5) kPa (p strumentation Laboratory, Lexington, Mas- Ppa=pulmonary arterial pressure; PVR=pulmonary vascular resistance; SVR=systemic vascular resistance; CI=cardiac index; Pa 2 =arterial oxygen tension; Sa 2 = arterial oxygen saturation; PPH=primary pulmonary hypertension; SPH=secondary pulmonary hypertension; thrombo=secondary to pulmonary thromboembolism; CFA = cryptogenic fibrosing alveolitis; W = warfarin; Dil = diltiazem.
group.bmj.com on June 24, 2017 -Published by http://thorax.bmj.com/ Downloaded from over, the use of two one-way valves ensured that patients were unable to re-breathe expired air. The Sa 2 and NO and NO 2 concentrations were monitored to avoid the development of hypoxia and NO and NO 2 toxicity. NO reacts with oxygen and forms NO 2 which can cause airway injury so NO was first mixed with nitrogen and then oxygen (fig 1) .
The study was dependent on the accuracy of the non-invasive measurements which were chosen to involve minimal disturbance to the haemodynamics of the study participants. The measurement of TcP 2 was first reported in 1969 by Huch et al. 13 The sensor allows measurement of TcP 2 which reflects the arterial oxygen pressure (Pa 2 ) 14 in many clinical conditions. We allowed 20 minutes exposure to each gas mixture which is sufficient for the fall in Pa 2 to be detected by the TcP 2 . 13 The low cardiac output and poor tissue perfusion cardiac output does not increase with inhaled NO.
4 6 7 As previously reported, cardiac output did not change in any of our patient groups <0.05) in patients with COPD. In patients (table 3) . The transthoracic impedance method with severe pulmonary hypertension TcP 2 of measuring cardiac output is valid in many was 7.6 (0.4) kPa with air and 7.4 (0.4) kPa patient groups 11 and in normal subjects 15 16 and with inhaled NO (p=0.68; fig 2) . No changes reliably follows the changes in cardiac output occurred in the TcP 2 , Sa 2 , or cardiac seen with exercise. 11 An additional explanation output in patients or volunteers with inhaled for the failure to improve TcP 2 in patients NO (table 3) . No significant changes in with severe pulmonary hypertension could be venous MetHb% level were observed during the existing vasodilator treatment which will inhaled NO (table 3) .
lessen the vasodilator effects of inhaled NO. Inhaled NO is a selective pulmonary vasodilator, 4-7 causing relaxation of smooth muscle Discussion cells of the pulmonary precapillary resistance In patients with COPD and in normal subjects arteries. 17 These vessels are found within the the TcP 2 fell during the 20 minute period of pulmonary acini and the distance of diffusion breathing 40 ppm of NO in air; no change in of inhaled NO into the smooth muscle of these TcP 2 occurred in patients with severe pulvessels is no greater than into the alveolar monary hypertension. These observations supcapillaries. Most of the inhaled NO is taken up port the idea that inhaled NO appears to worsen in alveolar capillaries where it combines rapidly gas exchange in those patients where the change with oxyhaemoglobin within red blood cells in pulmonary haemodynamics is small. to form methaemoglobin and nitrate. 18 19 The A concentration of 40 ppm inhaled NO was formation of methaemoglobin effectively inchosen on the basis of an isolated lung exactivates NO which has no subsequent action periment in which pretreatment with the NO on the systemic circulation. Our failure to demsynthase inhibitor N G -nitro--arginine caused onstrate a change in venous MetHb% agrees a fall in PVR which was normalised by 40 ppm with earlier work on short term exposure to and 80 ppm inhaled NO but not by 10 ppm.
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NO 5-7 and reflects the efficiency of the red blood To ensure that the correct concentration of NO cell methaemoglobin reductase in restoring iron was administered a nasal CPAP mask was used which is more airtight than a face mask. More-II haemoglobin. group.bmj.com on June 24, 2017 -Published by http://thorax.bmj.com/ Downloaded from Inhaled NO improves Pa 2 in certain lung other words, there is evidence that hypoxic vasoconstriction contributes to the matching diseases. In ARDS inhaled NO is distributed to ventilated regions of the lung where it increases of V/Q even in normal subjects.
It can be questioned whether pulmonary perfusion. Probably by a "steal" phenomenon, the inhaled NO lessens blood flow in regions endothelial NO subserves a similar function.
Whilst inhaled NO does not necessarily imof intrapulmonary shunt by diverting it from the unventilated regions 6 to ventilated regions. prove Pa 2 in patients with COPD, it is still effective in other chronic lung diseases. In On the other hand, the effect of aerosolised prostacyclin in ARDS has been reported to be patients with pulmonary fibrosis 30 inhaled NO improves arterial oxygenation. These patients, the same as inhaled NO. 20 However, there was still a larger decrease in systemic vascular re-however, behaved like the patients with severe pulmonary hypertension, with marked imsistance during aerosolised prostacyclin than during inhaled NO. In persistent pulmonary provement of pulmonary haemodynamics as well as a rise in Pa 2 . This serves to emphasise hypertension of the newborn the Pa 2 is also increased by inhaled NO. This is simply by the fact that important differences in the response of patients to inhaled NO depend upon reducing the pulmonary artery pressure which reverses the amount of right to left shunt the underlying pathophysiology of the lung disease. through the patient's ductus arteriosus.
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Patients with COPD do not have high values
In conclusion, inhaled NO is a selective pulmonary vasodilator with considerable theraof pulmonary vascular resistance 8 9 and have normal or even raised cardiac output. 21 Inhaled peutic potential. In many diseases it can also improve gas exchange, lessening hypoxaemia. NO will be expected to have only a minimal haemodynamic effect in these patients. One of In patients with COPD the gas exchange is not necessarily improved. Existing delivery systems the major abnormalities in patients with COPD is the disturbance of the distribution of vent-for inhaled NO do not selectively distribute NO to fast ventilated regions alone and so ilation. The homogeneity of the distribution of ventilation is reflected by the wide range of the benefits of hypoxic vasoconstriction are overridden. The same effect of inhaled NO time constants. 22 Conventional NO inhaled at a fixed concentration can be expected to reach in our volunteers suggests that an element of mismatching between V/Q driven by hypoxic regions with both slow and fast ventilation. Furthermore, in diseases such as emphysema vasoconstriction occurs even in the normal lung. collateral ventilation occurs. 23 We do not know the minimum alveolar concentration of inhaled 
